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A healthful eating pattern, regularphysical activity, and often pharma-cotherapy are key components of
diabetes management. For many individ-
uals with diabetes, the most challenging
part of the treatment plan is determin-
ing what to eat. It is the position of the
American Diabetes Association (ADA)
that there is not a “one-size-fits-all” eating
pattern for individuals with diabetes. The
ADA also recognizes the integral role of nu-
trition therapy in overall diabetes manage-
ment and has historically recommended
that each person with diabetes be actively
engaged in self-management, education,
and treatment planning with his or her
health care provider, which includes the
collaborative development of an individ-
ualized eating plan (1,2). Therefore, it is
important that all members of the health
care team be knowledgeable about dia-
betes nutrition therapy and support its
implementation.
This position statement on nutrition
therapy for individuals living with diabe-
tes replaces previous position statements,
the last of which was published in 2008
(3). Unless otherwise noted, research re-
viewed was limited to those studies con-
ducted in adults diagnosed with type 1 or
type 2 diabetes. Nutrition therapy for the
prevention of type 2 diabetes and for the
management of diabetes complications
and gestational diabetes mellitus is not
addressed in this review.
Agrading system,developedby theADA
and modeled after existing methods, was
utilized to clarify and codify the evidence that
forms the basis for the recommendations (1)
(Table 1). The level of evidence that supports
each recommendation is listed after the rec-
ommendation using the letters A, B, C, or E.
A table linking recommendations to evi-
dence can be reviewed at http://professional
.diabetes.org/nutrition.Members of theNu-
trition Recommendations Writing Group
Committee disclosed all potential financial
conflicts of interest with industry. These
disclosures were discussed at the onset of
the position statement development pro-
cess. Members of this committee, their em-
ployers, and their disclosed conflicts of
interest are listed in the ACKNOWLEDGMENTS.
The ADA uses general revenues to fund
development of its position statements
and does not rely on industry support for
these purposes.
Goals of nutrition therapy
that apply to adults
with diabetes
▪ To promote and support healthful eating
patterns, emphasizing a variety of nutrient-
dense foods in appropriate portion sizes,
in order to improve overall health and spe-
cifically to:
 Attain individualized glycemic, blood
pressure, and lipid goals. General
recommended goals from the ADA
for these markers are as follows:*
o A1C,7%.
o Blood pressure,140/80mmHg.
o LDL cholesterol ,100 mg/dL;
triglycerides ,150 mg/dL; HDL
cholesterol.40 mg/dL for men;
HDL cholesterol.50 mg/dL for
women.
 Achieve and maintain body weight
goals.
 Delay or prevent complications of
diabetes.
▪ To address individual nutrition needs
based on personal and cultural prefer-
ences, health literacy and numeracy,
access to healthful food choices, will-
ingness and ability to make behavioral
changes, as well as barriers to change.
▪ To maintain the pleasure of eating by
providing positive messages about food
choices while limiting food choices only
when indicated by scientific evidence.
▪ To provide the individual with diabe-
tes with practical tools for day-to-day
meal planning rather than focusing on
individual macronutrients, micronutri-
ents, or single foods.
*A1C, blood pressure, and cholesterol
goals may need to be adjusted for the in-
dividual based on age, duration of diabetes,
health history, and other present health
conditions. Further recommendations
for individualization of goals can be found
in the ADA Standards of Medical Care in
Diabetes (1).
Metabolic control can be considered
the cornerstone of diabetes management.
Achieving A1C goals decreases the risk for
microvascular complications (4,5) and
may also be important for cardiovascular
disease (CVD) risk reduction, particularly
in newly diagnosed patients (6–8). In ad-
dition, achieving blood pressure and lipid
goals can help reduce risk for CVD events
(9,10). Carbohydrate intake has a direct
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Table 1dNutrition therapy recommendations
Topic Recommendation Evidence rating
Effectiveness of nutrition
therapy
Nutrition therapy is recommended for all people with type 1 and type 2 diabetes as an
effective component of the overall treatment plan.
A
Individuals who have diabetes should receive individualized MNT as needed to achieve
treatment goals, preferably provided by an RD familiar with the components of diabetes
MNT.
A
o For individuals with type 1 diabetes, participation in an intensive flexible insulin
therapy education program using the carbohydrate counting meal planning approach
can result in improved glycemic control.
A
o For individuals using fixed daily insulin doses, consistent carbohydrate intake with
respect to time and amount can result in improved glycemic control and reduce risk for
hypoglycemia.
B
o A simple diabetes meal planning approach such as portion control or healthful food choices
may be better suited to individuals with type 2 diabetes identified with health and
numeracy literacy concerns. This may also be an effective meal planning strategy for older adults.
C
People with diabetes should receive DSME according to national standards and diabetes
self-management support when their diabetes is diagnosed and as needed thereafter.
B
Because diabetes nutrition therapy can result in cost savings (B) and improved outcomes such as
reduction in A1C (A), nutrition therapy should be adequately reimbursed by insurance and
other payers. (E)
B, A, E
Energy balance For overweight or obese adults with type 2 diabetes, reducing energy intake while
maintaining a healthful eating pattern is recommended to promote weight loss.
A
Modest weight loss may provide clinical benefits (improved glycemia, blood pressure, and/or
lipids) in some individuals with diabetes, especially those early in the disease process. To
achieve modest weight loss, intensive lifestyle interventions (counseling about nutrition




Evidence suggests that there is not an ideal percentage of calories from carbohydrate,
protein, and fat for all people with diabetes (B); therefore, macronutrient distribution
should be based on individualized assessment of current eating patterns, preferences,
and metabolic goals. (E)
B, E
Eating patterns A variety of eating patterns (combinations of different foods or food groups) are acceptable
for the management of diabetes. Personal preferences (e.g., tradition, culture, religion,
health beliefs and goals, economics) and metabolic goals should be considered when
recommending one eating pattern over another.
E
Carbohydrates Evidence is inconclusive for an ideal amount of carbohydrate intake for people with diabetes.
Therefore, collaborative goals should be developed with the individual with diabetes.
C
The amount of carbohydrates and available insulin may be the most important factor influencing
glycemic response after eating and should be considered when developing the eating plan.
A
Monitoring carbohydrate intake, whether by carbohydrate counting or experience-based
estimation remains a key strategy in achieving glycemic control.
B
For good health, carbohydrate intake from vegetables, fruits, whole grains, legumes, and dairy
products should be advised over intake from other carbohydrate sources, especially those
that contain added fats, sugars, or sodium.
B
Glycemic index and glycemic
load
Substituting low–glycemic load foods for higher–glycemic load foods may modestly improve
glycemic control.
C
Dietary fiber and whole grains People with diabetes should consume at least the amount of fiber and whole grains
recommended for the general public.
C
Substitution of sucrose for
starch
While substituting sucrose-containing foods for isocaloric amounts of other carbohydrates
may have similar blood glucose effects, consumption should be minimized to avoid
displacing nutrient-dense food choices.
A
Fructose Fructose consumed as “free fructose” (i.e., naturally occurring in foods such as fruit) may
result in better glycemic control compared with isocaloric intake of sucrose or starch (B),
and free fructose is not likely to have detrimental effects on triglycerides as long as intake is
not excessive (.12% energy). (C)
B, C
People with diabetes should limit or avoid intake of SSBs (from any caloric sweetener including
high fructose corn syrup and sucrose) to reduce risk for weight gain and worsening of
cardiometabolic risk profile.
B
Continued on p. 3823
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Table 1dContinued
Topic Recommendation Evidence rating
NNSs and hypocaloric
sweeteners
Use of NNSs has the potential to reduce overall calorie and carbohydrate intake if substituted
for caloric sweeteners without compensation by intake of additional calories from other
food sources.
B
Protein For people with diabetes and no evidence of diabetic kidney disease, evidence is
inconclusive to recommend an ideal amount of protein intake for optimizing glycemic
control or improving one or more CVD risk measures; therefore, goals should be
individualized.
C
For people with diabetes and diabetic kidney disease (either micro- or macroalbuminuria),
reducing the amount of dietary protein below usual intake is not recommended because it
does not alter glycemic measures, cardiovascular risk measures, or the course of GFR decline.
A
In individuals with type 2 diabetes, ingested protein appears to increase insulin response
without increasing plasma glucose concentrations. Therefore, carbohydrate sources high in
protein should not be used to treat or prevent hypoglycemia.
B
Total fat Evidence is inconclusive for an ideal amount of total fat intake for people with diabetes;
therefore, goals should be individualized (C); fat quality appears to be far more important
than quantity. (B)
C, B
MUFAs/PUFAs In people with type 2 diabetes, a Mediterranean-style, MUFA-rich eating pattern may benefit
glycemic control and CVD risk factors and can therefore be recommended as an effective
alternative to a lower-fat, higher-carbohydrate eating pattern.
B
Omega-3 fatty acids Evidence does not support recommending omega-3 (EPA and DHA) supplements for people
with diabetes for the prevention or treatment of cardiovascular events.
A
As recommended for the general public, an increase in foods containing long-chain omega-3
fatty acids (EPA and DHA) (from fatty fish) and omega-3 linolenic acid (ALA) is
recommended for individuals with diabetes because of their beneficial effects on lipoproteins,
prevention of heart disease, and associations with positive health outcomes in observational
studies.
B
The recommendation for the general public to eat fish (particularly fatty fish) at least two times
(two servings) per week is also appropriate for people with diabetes.
B
Saturated fat, dietary
cholesterol, and trans fat
The amount of dietary saturated fat, cholesterol, and trans fat recommended for people with
diabetes is the same as that recommended for the general population.
C
Plant stanols and sterols Individuals with diabetes and dyslipidemia may be able to modestly reduce total and LDL





There is no clear evidence of benefit from vitamin or mineral supplementation in people with
diabetes who do not have underlying deficiencies.
C
o Routine supplementation with antioxidants, such as vitamins E and C and carotene, is
not advised because of lack of evidence of efficacy and concern related to long-term
safety.
A
o There is insufficient evidence to support the routine use of micronutrients such as
chromium, magnesium, and vitamin D to improve glycemic control in people with
diabetes.
C
o There is insufficient evidence to support the use of cinnamon or other herbs/
supplements for the treatment of diabetes.
C
It is recommended that individualized meal planning include optimization of food choices to
meet recommended dietary allowance/dietary reference intake for all micronutrients.
E
Alcohol If adults with diabetes choose to drink alcohol, they should be advised to do so in
moderation (one drink per day or less for adult women and two drinks per day or
less for adult men).
E
Alcohol consumption may place people with diabetes at increased risk for delayed
hypoglycemia, especially if taking insulin or insulin secretagogues. Education and awareness
regarding the recognition and management of delayed hypoglycemia is warranted.
C
Sodium The recommendation for the general population to reduce sodium to less than 2,300 mg/day
is also appropriate for people with diabetes.
B
For individuals with both diabetes and hypertension, further reduction in sodium intake should
be individualized.
B
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effect on postprandial glucose levels in
people with diabetes and is the primary
macronutrient of concern in glycemic
management (11). In addition, an indi-
vidual’s food choices have a direct effect
on energy balance and, therefore, on body
weight, and food choices can also impact
blood pressure and lipid levels. Through
the collaborative development of individ-
ualized nutrition interventions and ongo-
ing support of behavior changes, health
care professionals can facilitate the
achievement of their patients’/clients’
health goals (11–13).
Diabetes nutrition
therapydIdeally, the individual with
diabetes should be referred to a registered
dietitian (RD) (or a similarly credentialed
nutrition professional if outside of the
U.S.) for nutrition therapy atdor soon
afterddiagnosis (11,14) and for ongoing
follow-up. Another option for many peo-
ple is referral to a comprehensive diabetes
self-management education (DSME) pro-
gram that includes instruction on nutrition
therapy. Unfortunately, a large percentage
of people with diabetes do not receive any
structured diabetes education and/or nutri-
tion therapy (15,16). National data indicate
that about half of the people with diabetes
report receiving some type of diabetes ed-
ucation (17) and even fewer see an RD. In
one study of 18,404 patients with diabetes,
only 9.1% had at least one nutrition visit
within a 9-year period (18). Many people
with diabetes, as well as their health care
provider(s), are not aware that these ser-
vices are available to them. Therefore this
position statement offers evidence-based
nutrition recommendations for all health
care professionals to use.
In 1999, the Institute of Medicine
(IOM) released a report concluding that
evidence demonstrates that medical nu-
trition therapy (MNT) can improve clini-
cal outcomes while possibly decreasing
the cost to Medicare of managing diabetes
(19). The IOM recommended that in-
dividualized MNT, provided by an RD
upon physician referral, be a covered
Medicare benefit as part of the multidisci-
plinary approach to diabetes care (19).
MNT is an evidence-based application of
the Nutrition Care Process provided by the
RD and is the legal definition of nutrition
counseling by an RD in the U.S. (20). The
IOM also defines nutrition therapy, which
has a broader definition than MNT (19).
Nutrition therapy is the treatment of a dis-
ease or condition through the modification
of nutrient or whole-food intake. The
definition does not specify that nutrition
therapy must be provided by an RD (19).
However, bothMNT and nutrition therapy
should involve a nutrition assessment,
nutrition diagnosis, nutrition interven-
tions (e.g., education and counseling),
and nutrition monitoring and evaluation
with ongoing follow-up to support long-
term lifestyle changes, evaluate out-
comes, and modify interventions as
needed (20).
Nutrition therapy studies included in
this position statement use a wide assort-
ment of nutrition professionals as well as
registered and advanced practice nurses
or physicians. Health care professionals
administering nutrition interventions in
studies conducted outside the U.S. did
not provide MNT as it is legally defined.
As a result, the decision was made to use
the term “nutrition therapy” rather than
“MNT” in this article, in an effort to be
more inclusive of the range of health pro-
fessionals providing nutrition interventions
and to recognize the broad definition of
nutrition therapy. However, the unique ac-
ademic preparation, training, skills, and
expertise of the RD make him/her the pre-
ferred member of the health care team to
provide diabetes MNT (Table 2).
Diabetes self-management
education/supportdIn addition
to diabetes MNT provided by an RD,
DSME and diabetes self-management
support (DSMS) are critical elements of
care for all people with diabetes and are
necessary to improve outcomes in a dis-
ease that is largely self-managed (21–26).
The National Standards for Diabetes Self-
Management Education and Support
recognize the importance of nutrition
as one of the core curriculum topics
taught in comprehensive programs. The
American Association of Diabetes Educa-
tors also recognizes the importance of
healthful eating as a core self-care behav-
ior (27). For more information, refer to
the ADA’s National Standards for Diabe-
tes Self-Management Education and
Support (21).
Effectiveness of nutrition therapy
c Nutrition therapy is recommended for
all people with type 1 and type 2 di-
abetes as an effective component of the
overall treatment plan. (A)
c Individuals who have diabetes should
receive individualized MNT as needed
to achieve treatment goals, preferably
provided by an RD familiar with the
components of diabetes MNT. (A)
o For individuals with type 1 diabetes,
participation in an intensive flexible
insulin therapy education program
using the carbohydrate counting
meal planning approach can result
in improved glycemic control. (A)
o For individuals using fixed daily
insulin doses, consistent carbohy-
drate intake with respect to time
and amount can result in improved
glycemic control and reduce the
risk for hypoglycemia. (B)
o A simple diabetes meal planning
approach such as portion control
or healthful food choices may be
better suited to individuals with
type 2 diabetes identified with
health and numeracy literacy con-
cerns. This may also be an effective
meal planning strategy for older
adults. (C)
c People with diabetes should receive
DSME according to national standards
and DSMS when their diabetes is diag-
nosed and as needed thereafter. (B)
c Because diabetes nutrition therapy can
result in cost savings (B) and improved
outcomes such as reduction in A1C
(A), nutrition therapy should be ade-
quately reimbursed by insurance and
other payers. (E)
The common coexistence of hyperlip-
idemia and hypertension in people with
diabetes requires monitoring of metabolic
Table 2dAcademy of Nutrition and
Dietetics Evidence-Based Nutrition Practice
Guidelines
Academy of Nutrition and Dietetics
Evidence-Based Nutrition Practice
Guidelines recommend the following
structure for the implementation of MNT
for adults with diabetes (11)
c A series of 3–4 encounters with an RD
lasting from 45–90 min.
c The series of encounters should begin at
diagnosis of diabetes or at first referral to an
RD for MNT for diabetes and should be
completed within 3–6 months.
c The RD should determine whether
additional MNT encounters are needed.
c At least 1 follow-up encounter is
recommended annually to reinforce
lifestyle changes and to evaluate and
monitor outcomes that indicate the need for
changes in MNT or medication(s); an RD
should determine whether additional MNT
encounters are needed.
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parameters (e.g., glucose, lipids, blood
pressure, body weight, renal function) to
ensure successful health outcomes (28).
Nutrition therapy that includes the devel-
opment of an eating pattern designed to
lower glucose, blood pressure, and alter
lipid profiles is important in the manage-
ment of diabetes as well as lowering the
risk of CVD, coronary heart disease, and
stroke. Successful approaches should also
include regular physical activity and be-
havioral interventions to help sustain im-
proved lifestyles (11).
Findings from randomized con-
trolled trials (RCTs) and from systematic
and Cochrane reviews demonstrate the
effectiveness of nutrition therapy for im-
proving glycemic control and various
markers of cardiovascular and hyperten-
sion risk (13,14,29–46). In the general
population, MNT provided by an RD to
individuals with an abnormal lipid profile
has been shown to reduce daily fat (5–
8%), saturated fat (2–4%), and energy
intake (232–710 kcal/day), and lower tri-
glycerides (11–31%), LDL cholesterol
(7–22%), and total cholesterol (7–21%)
levels (47).
Effective nutrition therapy interven-
tions may be a component of a compre-
hensive group diabetes education program
or an individualized session (14,29–
38,40–42,44,45). Reported A1C reduc-
tions are similar or greater thanwhat would
be expected with treatment with currently
available pharmacologic treatments for di-
abetes. The documented decreases in A1C
observed in these studies are type 1 diabe-
tes:20.3 to21% (13,39,43,48) and type 2
diabetes: 20.5 to 22% (5,14,29–38,40–
42,44,45,49).
Due to the progressive nature of type
2 diabetes, nutrition and physical activity
interventions alone (i.e., without pharma-
cotherapy) are generally not adequately
effective in maintaining persistent glyce-
mic control over time for many individu-
als. However, after pharmacotherapy is
initiated, nutrition therapy continues to be
an important component of the overall
treatment plan (2). For individualswith type
1 diabetes using multiple daily injections or
continuous subcutaneous insulin infusion, a
primary focus for nutrition therapy should
be on how to adjust insulin doses based on
planned carbohydrate intake (13,39,43,50–
53). For individuals using fixed daily insulin
doses, carbohydrate intake on a day-to-day
basis should be consistent with respect to
time and amount (54,55). Intensive insulin
management education programs that in-
clude nutrition therapy have been shown
to reduce A1C (13). Retrospective studies
reveal durable A1C reductions with these
types of programs (51,56) and significant
improvements in quality of life (57) over
time. Finally, nutritional approaches
for reducing CVD risk, including opti-
mizing serum lipids and blood pressure,
can effectively reduce CVD events and
mortality (1).
Energy balance
c For overweight or obese adults with
type 2 diabetes, reducing energy intake
while maintaining a healthful eating
pattern is recommended to promote
weight loss. (A)
c Modest weight loss may provide clini-
cal benefits (improved glycemia, blood
pressure, and/or lipids) in some indi-
viduals with diabetes, especially those
early in the disease process. To achieve
modest weight loss, intensive lifestyle
interventions (counseling about nutri-
tion therapy, physical activity, and be-
havior change) with ongoing support are
recommended. (A)
More than three out of every four
adults with diabetes are at least over-
weight (17), and nearly half of individuals
with diabetes are obese (58). Because of
the relationship between body weight
(i.e., adiposity) and insulin resistance,
weight loss has long been a recommended
strategy for overweight or obese adults
with diabetes (1). Prevention of weight
gain is equally important. Long-term re-
duction of adiposity is difficult for most
people to achieve, and even harder for
individuals with diabetes to achieve
given the impact of some medications
used to improve glycemic control (e.g.,
insulin, insulin secretagogues, and thia-
zolidinediones) (59,60). A number of fac-
tors may be responsible for increasing
adiposity in people with diabetes,
including a reduction in glycosuria and
thus retention of calories otherwise lost
as an effect of therapeutic intervention,
changes in food intake, or changes in en-
ergy expenditure (61–64). If adiposity
is a concern, medications that are weight
neutral or weight reducing (e.g., metfor-
min, incretin-based therapies, sodium
glucose co-transporter 2 [SGLT-2] in-
hibitors) could be considered. Several
intensive DSME and nutrition interven-
tion studies show that glycemic control
can be achieved while maintaining weight
or even reducing weight when ap-
propriate lifestyle counseling is provided
(14,31,35,41,42,44,45,50,65,66).
In interventional studies lasting 12
months or longer and targeting individu-
als with type 2 diabetes to reduce excess
body weight (35,67–75), modest weight
losses were achieved ranging from 1.9 to
8.4 kg. In the Look AHEAD trial, at study
end (;10 years), the mean weight loss
from baseline was 6% in the intervention
group and 3.5% in the control group
(76,77). Studies designed to reduce ex-
cess body weight have used a variety of
energy-restricted eating patterns with vari-
ousmacronutrient intakes and occasionally
included a physical activity component
and ongoing follow-up support. Studies
achieving the greatest weight losses, 6.2
kg and 8.4 kg, respectively, included the
Mediterranean-style eating pattern (72)
and a study testing a comprehensiveweight
loss program that involved diet (including
meal replacements) and physical activity
(76). In the studies reviewed, improve-
ments in A1C were noted to persist at 12
months in eight intervention groups within
five studies (67,69,72,73,76); however, in
one of the studies including data at 18
months, the A1C improvement was not
maintained (69). The Mediterranean-
style eating pattern reported the largest
improvement of A1C at 1 year (21.2%)
(72), and the Look AHEAD study inten-
sive lifestyle intervention reported the
next largest improvement (20.64%) (76).
One of these studies included only individ-
uals with newly diagnosed diabetes (72),
and the other included predominantly in-
dividuals with diabetes early in the disease
process (,30% were on insulin) (76). Sig-
nificant improvements in A1C at 1 year
were also reported in other studies using
energy-restricted eating plans; these studies
used meal replacements (67), or low-fat
(72)/high-protein (73), or high-carbohydrate
eating patterns (73). Not all weight loss in-
terventions reviewed led to improvements
in A1C at 1 year (35,68,70,71,74,75), al-
though these studies tended to achieve less
weight loss.
Among the studies reviewed, the most
consistently reported significant changes of
reducing excess body weight on cardiovas-
cular risk factors were an increase in HDL
cholesterol (67,72,73,75–77), a decrease in
triglycerides (72,73,76–78), and a decrease
in blood pressure (67,70,72,75–77). De-
spite some improvements in cardiovascular
risk factors, the Look AHEAD trial failed to
demonstrate reduction in CVD events
among individuals randomized to an inten-
sive lifestyle intervention for sustained
weight loss (77). Of note, however, those
randomized to the intervention experienced
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statistically significant weight loss, requiring
less medication for glycemic control and
management of CVD risk factors, and expe-
rienced several additional health benefits
(e.g., reduced sleep apnea, depression,
and urinary incontinence and improved
health-related quality of life) (79–82).
Intensive lifestyle programs (ongoing,
with frequent follow-up) are required to
achieve significant reductions in excess
body weight and improvements in A1C,
blood pressure, and lipids (76,83).
Weight loss appears to be most beneficial
for individuals with diabetes early in the
disease process (72,76,83). In the Look
AHEAD study, participants with early-
stage diabetes (shortest duration, not treated
with insulin, good baseline glycemic con-
trol) received the most health benefits
with a small percentage of individuals
achieving partial or complete diabetes re-
mission (84). It is unclear if the benefits
result from the reduction in excess weight
or the energy restriction or both. Long-
term maintenance of weight, following
weight reduction, is possible, but research
suggests it requires an intensive program
with long-term support. Many individuals
do regain a portion of their initial weight
loss (77,85). Factors contributing to the
individual’s inability to retain maximal
weight loss include socioeconomic status,
an unsupportive environment, and phys-
iological changes (e.g., compensatory
changes in circulating hormones that en-
courage weight regain after weight loss is
achieved) (86).
The optimal macronutrient intake to
support reduction in excess body weight
has not been established. Thus, the cur-
rent state of the literature does not sup-
port one particular nutrition therapy
approach to reduce excess weight, but
rather a spectrum of eating patterns that
result in reduced energy intake. A weight
loss of .6 kg (approximately a 7–8.5%
loss of initial body weight), regular phys-
ical activity, and frequent contact with
RDs appear important for consistent
beneficial effects of weight loss interven-
tions (85). In the Look AHEAD study,
weight loss strategies associated with lower
BMI in overweight or obese individuals
with type 2 diabetes included weekly self-
weighing, regular consumption of break-
fast, and reduced intake of fast foods (87).
Other successful strategies included in-
creasing physical activity, reducing portion
sizes, using meal replacements (as appro-
priate), and encouraging individuals with
diabetes to eat those foods with the greatest
consensus for improving health.
Health professionals should collab-
orate with individuals with diabetes to
integrate lifestyle strategies that prevent
weight gain or promote modest, realistic
weight loss. The emphases of education
and counseling should be on the devel-
opment of behaviors that support long-
term weight loss or weight maintenance
with less focus on the outcome of weight
loss. Bariatric surgery is recognized as an
option for individuals with diabetes who
meet the criteria for surgery and is not
covered in this review. For recommen-
dations on bariatric surgery, see the ADA
Standards of Medical Care (1).
Optimal mix of macronutrients
c Evidence suggests that there is not an
ideal percentage of calories from car-
bohydrate, protein, and fat for all people
with diabetes (B); therefore, macronu-
trient distribution should be based on
individualized assessment of current
eating patterns, preferences, and met-
abolic goals. (E)
Although numerous studies have at-
tempted to identify the optimal mix of
macronutrients for the meal plans of
people with diabetes, a systematic review
(88) found that there is no ideal mix that
applies broadly and that macronutrient
proportions should be individualized.
On average, it has been observed that peo-
ple with diabetes eat about 45% of their cal-
ories from carbohydrate, ;36–40% of
calories from fat, and the remainder
(;16–18%) from protein (89–91). Regard-
less of the macronutrient mix, total energy
intake shouldbe appropriate toweightman-
agement goals. Further, individualization of
the macronutrient composition will depend
on the metabolic status of the individual
(e.g., lipid profile, renal function) and/or
food preferences. A variety of eating patterns
have been shown modestly effective in man-
agingdiabetes includingMediterranean-style,
Dietary Approaches to Stop Hypertension
(DASH) style, plant-based (vegan or vege-
tarian), lower-fat, and lower-carbohydrate
patterns (36,46,72,92,93).
Eating patterns
c Avariety of eating patterns (combinations
of different foods or food groups) are
acceptable for the management of di-
abetes. Personal preferences (e.g., tra-
dition, culture, religion, health beliefs
and goals, economics) and metabolic
goals should be considered when
recommending one eating pattern
over another. (E)
Eating patterns, also called dietary pat-
terns, is a termused todescribe combinations
of different foods or food groups that
characterize relationships between nutri-
tion and health promotion and disease
prevention (94). Individuals eat combina-
tions of foods, not single nutrients, and
thus it is important to study diet and dis-
ease relationships (95). Factors impacting
eating patterns include, but are not limited
to, food access/availability of healthful
foods, tradition, cultural food systems,
health beliefs, knowledge of foods that
promote health and prevent disease, and
economics/resources to buy health-
promoting foods (95).
Eating patterns have also evolved
over time to include patterns of food
intake among specific populations to
eating patterns prescribed to improve
health. Patterns naturally occurring
within populations based on food avail-
ability, culture, or tradition and those
prescribed to prevent or manage health
conditions are important to research.
Eating patterns studied among individu-
als with type 1 or type 2 diabetes were
reviewed to evaluate their impact on di-
abetes nutrition goals. The following eat-
ing patterns (Table 3) were reviewed:
Mediterranean, vegetarian, low fat, low
carbohydrate, and DASH.
The Mediterranean-style eating pat-
tern, mostly studied in the Mediterranean
region, has been observed to improve car-
diovascular risk factors (i.e., lipids, blood
pressure, triglycerides) (11,72,88,100) in
individuals with diabetes and lower com-
bined endpoints for CVD events and stroke
(83) when supplemented with mixed nuts
(including walnuts, almonds, and hazel-
nuts) or olive oil. Individuals following an
energy-restricted Mediterranean-style eat-
ing pattern also achieve improvements in
glycemic control (88). Given that the stud-
ies are mostly in the Mediterranean region,
further research is needed to determine if
the study results can be generalized to
other populations and if similar levels of
adherence to the eating pattern can be
achieved.
Six vegetarian and low-fat vegan stud-
ies (36,93,101–103,131) in individuals
with type 2 diabetes were reviewed. Stud-
ies ranged in duration from 12 to 74
weeks, and the diets did not consistently
improve glycemic control or CVD risk
factors except when energy intake was re-
stricted and weight was lost. Diets often
did result in weight loss (36,101–
103,131). More research on vegan and
vegetarian diets is needed to assess diet
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quality given studies often focus more
on what is not consumed than what is
consumed.
The low-fat eating pattern is one that
has often been encouraged as a strategy to
lose weight or to improve cardiovascular
health within the U.S. In the Look AHEAD
trial (77), an energy-reduced low-fat eating
pattern was encouraged for weight loss,
and individuals achieved moderate success
(76). However, in a systematic review (88)
and in four studies (70,71,75,103a) and in
a meta-analysis (103b) published since the
systematic review, lowering total fat intake
did not consistently improve glycemic con-
trol or CVD risk factors. Benefit from a low-
fat eating pattern appears to be more likely
when energy intake is also reduced and
weight loss occurs (76,77).
For a review of the studies focused
on a low-carbohydrate eating pattern, see
the CARBOHYDRATES section. Currently
there is inadequate evidence in isocaloric
comparison recommending a specific
amount of carbohydrates for people
with diabetes.
In people without diabetes, the DASH
eating plan has been shown to help
control blood pressure and lower risk
for CVD and is frequently recommended
as a healthful eating pattern for the gen-
eral population (104–106). Limited
evidence exists on the effects of the DASH
eating plan on health outcomes specifically
in individuals with diabetes; however, one
would expect similar results to other stud-
ies using the DASH eating plan. In one
small study in people with type 2 diabetes,
the DASH eating plan, which included a
sodium restriction of 2,300 mg/day, im-
proved A1C, blood pressure, and other
cardiovascular risk factors (46). The blood
pressure benefits are thought to be due to
the total eating pattern, including the re-
duction in sodium and other foods and
nutrients that have been shown to influ-
ence blood pressure (99,105).
The evidence suggests that several
different macronutrient distributions/
eating patterns may lead to improve-
ments in glycemic and/or CVD risk
factors (88). There is no “ideal” conclu-
sive eating pattern that is expected to
benefit all individuals with diabetes
(88). Total energy intake (and thus por-
tion sizes) is an important consideration
no matter which eating pattern the indi-
vidual with diabetes chooses to eat. Be-
cause dietary patterns are influenced by
food availability, perception of health-
fulness of certain foods and by the indi-
vidual’s preferences, culture, religion,
knowledge, health beliefs, and access
to food and resources (e.g., budget/
income) (95), these factors should be




c Evidence is inconclusive for an ideal
amount of carbohydrate intake for peo-
ple with diabetes. Therefore, collabora-
tive goals should be developed with the
individual with diabetes. (C)
c The amount of carbohydrates and avail-
able insulin may be the most important
factor influencing glycemic response after
eating and should be considered when
developing the eating plan. (A)
c Monitoring carbohydrate intake, whether
by carbohydrate counting or experience-
based estimation, remains a key strategy in
achieving glycemic control. (B)
c For good health, carbohydrate intake
from vegetables, fruits, whole grains,
legumes, and dairy products should
be advised over intake from other
carbohydrate sources, especially
those that contain added fats, sugars,
or sodium. (B)
Evidence is insufficient to support one
specific amount of carbohydrate intake for
all people with diabetes. Collaborative
Table 3dReviewed eating patterns
Type of eating pattern Description
Mediterranean style (96) Includes abundant plant food (fruits, vegetables, breads, other forms of cereals, beans, nuts and seeds); minimally
processed, seasonally fresh, and locally grown foods; fresh fruits as the typical daily dessert and concentrated
sugars or honey consumed only for special occasions; olive oil as the principal source of dietary lipids; dairy
products (mainly cheese and yogurt) consumed in low to moderate amounts; fewer than 4 eggs/week; red meat
consumed in low frequency and amounts; and wine consumption in low to moderate amounts generally
with meals.
Vegetarian and vegan (97) The twomost commonways of defining vegetarian diets in the research are vegan diets (diets devoid of all flesh foods
and animal-derived products) and vegetarian diets (diets devoid of all flesh foods but including egg [ovo] and/or
dairy [lacto] products). Features of a vegetarian-eating pattern that may reduce risk of chronic disease include
lower intakes of saturated fat and cholesterol and higher intakes of fruits, vegetables, whole grains, nuts, soy
products, fiber, and phytochemicals.
Low fat (98) Emphasizes vegetables, fruits, starches (e.g., breads/crackers, pasta, whole grains, starchy vegetables), lean protein,
and low-fat dairy products. Defined as total fat intake,30% of total energy intake and saturated fat intake,10%.
Low carbohydrate (88) Focuses on eating foods higher in protein (meat, poultry, fish, shellfish, eggs, cheese, nuts and seeds), fats (oils,
butter, olives, avocado), and vegetables low in carbohydrate (salad greens, cucumbers, broccoli, summer squash).
The amount of carbohydrate allowed varies with most plans allowing fruit (e.g., berries) and higher carbohydrate
vegetables; however, sugar-containing foods and grain products such as pasta, rice, and bread are generally
avoided. There is no consistent definition of “low” carbohydrate. In research studies, definitions have ranged from
very low-carbohydrate diet (21–70 g/day of carbohydrates) to moderately low-carbohydrate diet (30 to,40% of
calories from carbohydrates).
DASH (99) Emphasizes fruits, vegetables, and low-fat dairy products, including whole grains, poultry, fish, and nuts and is
reduced in saturated fat, redmeat, sweets, and sugar-containing beverages. The most effective DASH diet was also
reduced in sodium.
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goals should be developed with each per-
son with diabetes. Some published studies
comparing lower levels of carbohydrate
intake (ranging from 21 g daily up to
40% of daily energy intake) to higher
carbohydrate intake levels indicated im-
proved markers of glycemic control and
insulin sensitivity with lower carbohy-
drate intakes (92,100,107–111). Four
RCTs indicated no significant difference in
glycemic markers with a lower-carbohydrate
diet compared with higher carbohydrate
intake levels (71,112–114). Many of these
studies were small, were of short duration,
and/or had low retention rates (92,107,
109,110,112,113).
Some studies comparing lower levels
of carbohydrate intake to higher carbo-
hydrate intake levels revealed improve-
ments in serum lipid/lipoproteinmeasures,
including improved triglycerides, VLDL
triglyceride, and VLDL cholesterol, total
cholesterol, and HDL cholesterol levels
(71,92,100,107,109,111,112,115). A
few studies found no significant differ-
ence in lipids and lipoproteins with a
lower-carbohydrate diet compared with
higher carbohydrate intake levels. It
should be noted that these studies had
low retention rates, which may lead to
loss of statistical power and biased results
(110,113,116). In many of the reviewed
studies, weight loss occurred, confound-
ing the interpretation of results from ma-
nipulation of macronutrient content.
Despite the inconclusive results of
the studies evaluating the effect of dif-
fering percentages of carbohydrates in
people with diabetes, monitoring carbo-
hydrate amounts is a useful strategy for
improving postprandial glucose control.
Evidence exists that both the quantity
and type of carbohydrate in a food in-
fluence blood glucose level, and total
amount of carbohydrate eaten is the
primary predictor of glycemic response
(55,114,117–122). In addition, lower
A1C occurred in the Diabetes Control
and Complications Trial (DCCT) intensive-
treatment group and the Dose Adjustment
For Normal Eating (DAFNE) trial partici-
pants who received nutrition therapy that
focused on the adjustment of insulin doses
based on variations in carbohydrate intake
and physical activity (13,123).
As for the general U.S. population,
carbohydrate intake from vegetables,
fruits, whole grains, legumes, and milk
should be encouraged over other sources of
carbohydrates, or sources with added fats,
sugars, or sodium, in order to improve
overall nutrient intake (105).
Quality of carbohydrates
Glycemic index and glycemic load
c Substituting low–glycemic load foods
for higher–glycemic load foods may
modestly improve glycemic control. (C)
The ADA recognizes that education
about glycemic index and glycemic load
occurs during the development of indi-
vidualized eating plans for people with
diabetes. Some organizations specifically
recommend use of low–glycemic index
diets (124,125). However the literature
regarding glycemic index and glycemic
load in individuals with diabetes is com-
plex, and it is often difficult to discern the
independent effect of fiber comparedwith
that of glycemic index on glycemic con-
trol or other outcomes. Further, studies
used varying definitions of low and high
glycemic index (11,88,126), and glyce-
mic response to a particular food varies
among individuals and can also be af-
fected by the overall mixture of foods con-
sumed (11,126).
Some studies did not show improve-
ment with a lower–glycemic index eating
pattern; however, several other studies
using low–glycemic index eating patterns
have demonstrated A1C decreases of
20.2 to 20.5%. However, fiber intake
was not consistently controlled, thereby
making interpretation of the findings dif-
ficult (88,118,119,127). Results on CVD
risk measures are mixed with some show-
ing the lowering of total or LDL choles-
terol and others showing no significant
changes (120).
Dietary fiber and whole grains
c People with diabetes should consume
at least the amount of fiber and whole
grains recommended for the general
public. (C)
Intake of dietary fiber is associated
with lower all-cause mortality (128,129)
in people with diabetes. Two systematic
reviews found little evidence that fiber
significantly improves glycemic control
(11,88). Studies published since these re-
views have shown modest lowering of
preprandial glucose (130) and A1C
(20.2 to 20.3%) (119,130) with intakes
of .50 g of fiber/day. Most studies on
fiber in people with diabetes are of short
duration, have a small sample size, and
evaluate the combination of high-fiber
and low–glycemic index foods, and in
some cases weight loss, making it difficult
to isolate fiber as the sole determinant of
glycemic improvement (119,131–133). Fi-
ber intakes to improve glycemic control,
based on existing research, are also unreal-
istic, requiring fiber intakes of.50 g/day.
Studies examining fiber’s effect on
CVD risk factors are mixed; however, to-
tal fiber intake, especially from natural
food sources (vs. supplements), seems
to have a beneficial effect on serum cho-
lesterol levels and other CVD risk factors
such as blood pressure (11,88,134). Be-
cause of the general health benefits of fi-
ber, recommendations for the general
public to increase intake to 14 g fiber/
1,000 kcals daily or about 25 g/day for
adult women and 38 g/day for adult
men are encouraged for individuals with
diabetes (105).
Research has also compared the ben-
efits of whole grains to fiber. The Dietary
Guidelines for Americans, 2010 defines
whole grains as foods containing the en-
tire grain seed (kernel), bran, germ, and
endosperm (105). A systematic review
(88) concluded that the consumption of
whole grains was not associated with im-
provements in glycemic control in indi-
viduals with type 2 diabetes; however, it
may have other benefits, such as reduc-
tions in systemic inflammation. Data from
the Nurses’ Health Study examining
whole grains and their components (ce-
real fiber, bran, and germ) in relation to
all-cause and CVD-specific mortality
among women with type 2 diabetes
suggest a potential benefit of whole-grain
intake in reducing mortality and CVD
(128). As with the general population, in-
dividuals with diabetes should consume
at least half of all grains as whole grains
(105).
Resistant starch and
fructansdResistant starch is defined
as starch physically enclosed within intact
cell structures as in some legumes, starch
granules as in raw potato, and retrograde
amylose from plants modified by plant
breeding to increase amylose content. It
has been proposed that foods containing
resistant starch or high amylose foods
such as specially formulated cornstarch
may modify postprandial glycemic re-
sponse, prevent hypoglycemia, and re-
duce hyperglycemia. However, there are
no published long-term studies in sub-
jects with diabetes to prove benefit from
the use of resistant starch.
Fructans are an indigestible type of
fiber that has been hypothesized to have a
glucose-lowering effect. Inulin is a fructan
commonly added tomany processed food
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products in the form of chicory root.
Limited research in people with diabetes
is available. One systematic review that
included three short-term studies in peo-
ple with diabetes showed mixed results of
fructan intake on glycemia. There are no
published long-term studies in subjects
with diabetes to prove benefit from the
use of fructans (135).
Substitution of sucrose for starch
c While substituting sucrose-containing
foods for isocaloric amounts of other
carbohydrates may have similar blood
glucose effects, consumption should be
minimized to avoid displacing nutrient-
dense food choices. (A)
Sucrose is a disaccharide made of
glucose and fructose. Commonly known
as table sugar or white sugar, it is found
naturally in sugar cane and in sugar beets.
Research demonstrates that substitution of
sucrose for starch for up to 35% of calories
may not affect glycemia or lipid levels (11).
However, because foods high in sucrose are
generally high in calories, substitution
should bemade in the context of an overall
healthful eating pattern with caution not to
increase caloric intake. Additionally, as
with all people, selection of foods contain-
ing sucrose or starch should emphasize
more nutrient-dense foods for an overall
healthful eating pattern (105).
Fructose
c Fructose consumed as “free fructose”
(i.e., naturally occurring in foods such
as fruit) may result in better glycemic
control compared with isocaloric intake
of sucrose or starch (B), and free fructose
is not likely to have detrimental effects
on triglycerides as long as intake is not
excessive (.12% energy). (C)
c People with diabetes should limit or
avoid intake of sugar-sweetened bev-
erages (SSBs) (from any caloric sweet-
ener including high-fructose corn syrup
and sucrose) to reduce risk for weight
gain and worsening of cardiometabolic
risk profile. (B)
Fructose is a monosaccharide found
naturally in fruits. It is also a component
of added sugars found in sweetened
beverages and processed snacks. The
term “free fructose” refers to fructose
that is naturally occurring in foods such
as fruit and does not include the fructose
that is found in the formof the disaccharide
sucrose, nor does it include the fructose in
high-fructose corn syrup.
Based on two systematic reviews and
meta-analyses of studies conducted in
persons with diabetes, it appears that
free fructose (naturally occurring from
foods such as fruit) consumption is not
more deleterious than other forms of
sugar unless intake exceeds approxi-
mately 12% of total caloric intake
(136,137). Many foods marketed to peo-
ple with diabetes may contain large
amounts of fructose (such as agave nec-
tar); these foods should not be consumed
in large amounts to avoid excess caloric
intake and to avoid excessive fructose
intake.
In terms of glycemic control, Cozma
et al. (138) conducted a systemic review
and meta-analysis of controlled feeding
trials to study the impact of fructose on
glycemic control compared with other
sources of carbohydrates. Based on 18 tri-
als, the authors found that isocaloric ex-
change of fructose for carbohydrates
reduced glycated blood proteins and did
not significantly affect fasting glucose or
insulin. However, it was noted that appli-
cability may be limited because most of
the trials were less than 12 weeks in du-
ration. With regard to the treatment of
hypoglycemia, in a small study comparing
glucose, sucrose, or fructose, Husband
et al. (139) found that fructose was the
least effective in eliciting the desired up-
ward correction of the blood glucose.
Therefore, sucrose or glucose in the form
of tablets, liquid, or gel may be the pre-
ferred treatment over fruit juice, although
availability and convenience should be
considered.
There is now abundant evidence from
studies of individuals without diabetes
that because of their high amounts of
rapidly absorbable carbohydrates (such as
sucrose or high-fructose corn syrup),
large quantities of SSBs should be avoided
to reduce the risk for weight gain and
worsening of cardiometabolic risk factors
(140–142). Evidence suggests that con-
suming high levels of fructose-containing
beverages may have particularly adverse ef-
fects on selective deposition of ectopic and
visceral fat, lipid metabolism, blood pres-
sure, insulin sensitivity, and de novo lipo-
genesis, compared with glucose-sweetened
beverages (142). In terms of specific effects
of fructose, concern has been raised re-
garding elevations in serum triglycerides
(143,144). Such studies are not available
among individuals with diabetes; how-
ever, there is little reason to suspect that
the diabetic state would mitigate the ad-
verse effects of SSBs.
Nonnutritive sweeteners and
hypocaloric sweeteners
c Use of nonnutritive sweeteners (NNSs)
has the potential to reduce overall calorie
and carbohydrate intake if substituted for
caloric sweeteners without compensation
by intake of additional calories fromother
food sources. (B)
The U.S. Food and Drug Administra-
tion has reviewed several types of hypo-
caloric sweeteners (e.g., NNSs and sugar
alcohols) for safety and approved them
for consumption by the general public,
including people with diabetes (145).
Research supports that NNSs do not
produce a glycemic effect; however, foods
containing NNSs may affect glycemia
based on other ingredients in the product
(11). An American Heart Association and
ADA scientific statement on NNS con-
sumption concludes that there is not
enough evidence to determine whether
NNS use actually leads to reduction in
body weight or reduction in cardiome-
tabolic risk factors (146). These conclu-
sions are consistent with a systematic
review of hypocaloric sweeteners (in-
cluding sugar alcohols) that found little
evidence that the use of NNSs lead to
reductions in body weight (147). If NNSs
are used to replace caloric sweeteners,
without caloric compensation, then NNSs
may be useful in reducing caloric and
carbohydrate intake (146), although fur-
ther research is needed to confirm these
results (147).
Protein
c For people with diabetes and no evi-
dence of diabetic kidney disease, evi-
dence is inconclusive to recommend an
ideal amount of protein intake for op-
timizing glycemic control or improving
one or more CVD risk measures; there-
fore, goals should be individualized. (C)
c For people with diabetes and diabetic
kidney disease (either micro- or macro-
albuminuria), reducing the amount of
dietary protein below the usual intake
is not recommended because it does
not alter glycemic measures, cardio-
vascular risk measures, or the course
of glomerular filtration rate (GFR)
decline. (A)
c In individuals with type 2 diabetes,
ingested protein appears to increase
insulin response without increasing
plasma glucose concentrations. Therefore,
carbohydrate sources high in protein
should not be used to treat or prevent
hypoglycemia. (B)
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Several RCTs have examined the ef-
fect of higher protein intake (28–40% of
total energy) to usual protein intake (15–
19% total) on diabetes outcomes. One
study demonstrated decreased A1C
with a higher-protein diet (148). How-
ever, other studies showed no effect on
glycemic control (149–151). Some trials
comparing higher protein intakes to usual
protein intake have shown improved lev-
els of serum triglycerides, total choles-
terol, and/or LDL cholesterol (148,150).
However, two trials reported no improve-
ment in CVD risk factors (149,151). Fac-
tors affecting interpretation of this research
include small sample sizes (148,151) and
study durations of less than 6 months
(148–150).
Several RCTs comparing protein lev-
els in individuals with diabetic kidney
disease with either micro- or macroalbu-
minuria had adequately large sample sizes
and durations for interpretation. Four
studies reported no difference in GFR
and/or albumin excretion rate (152–155),
while one smaller study found some po-
tentially beneficial renal effects with a
low-protein diet (156). Two meta-analyses
found no clear benefits on renal parameters
from low-protein diets (157,158). One fac-
tor affecting interpretation of these studies
was that actual protein intake differed from
goal protein intake. Two studies reported
higher actual protein intake in the lower
protein group than in the control groups.
None of the five reviewed studies since
2000 demonstrated malnourishment as
evidenced by hypoalbuminemia with low-
protein diets, but both meta-analyses
found evidence for this in earlier studies.
There is very limited research in
people with diabetes and without kid-
ney disease on the impact of the type of
protein consumed. One study did not
find a significant difference in glycemic
or lipid measures when comparing a
chicken- or red meat–based diet (156).
For individuals with diabetic kidney dis-
ease andmacroalbuminuria, changing the
source of protein to be more soy-based
may improve CVD risk factors but does
not appear to alter proteinuria (159,160).
For individuals with type 2 diabetes,
protein does not appear to have a sig-
nificant effect on blood glucose level
(161,162) but does appear to increase in-
sulin response (161,163,164). For this
reason, it is not advised to use protein to
treat hypoglycemia or to prevent hypo-
glycemia. Protein’s effect on blood glu-
cose levels in type 1 diabetes is less clear
(165,166).
Total fat
c Evidence is inconclusive for an ideal
amount of total fat intake for people
with diabetes; therefore goals should
be individualized (C); fat quality ap-
pears to be far more important than
quantity. (B)
Currently, insufficient data exist to
determine a defined level of total energy
intake from fat at which risk of inade-
quacy or prevention of chronic disease
occurs, so there is no adequate intake or
recommended daily allowance for total fat
(167). However, the IOM did define an
acceptable macronutrient distribution
range (AMDR) for total fat of 20–35% of
energy with no tolerable upper intake
level defined. This AMDR for total fat
was “estimated based on evidence
indicating a risk for CHD [coronary heart
disease] at low intake of fat and high in-
takes of carbohydrate and on evidence for
increased obesity and its complications
(CHD) at high intakes of fat” (167). These
recommendations are not diabetes-specific;
however, limited research exists in individ-
uals with diabetes. Fatty acids are catego-
rized as being saturated or unsaturated
(monounsaturated or polyunsaturated).
Trans fatty acids may be unsaturated,
but they are structurally different and
have negative health effects (105). The
type of fatty acids consumed is more im-
portant than total fat in the diet in terms
of supporting metabolic goals and influ-
encing the risk of CVD (83,105,168);
thus more attention should be given to
the type of fat intake when individualiz-
ing goals. Individuals with diabetes
should be encouraged to moderate their
fat intakes to be consistent with their
goals to lose or maintain weight.
Monounsaturated fatty acids/
polyunsaturated fatty acids
c In people with type 2 diabetes, a
Mediterranean-style, monounsaturated
fatty acid (MUFA)-rich eating pattern
may benefit glycemic control and CVD
risk factors and can, therefore, be rec-
ommended as an effective alternative to
a lower-fat, higher-carbohydrate eating
pattern. (B)
Evidence from large prospective cohort
studies, clinical trials, and a systematic
review of RCTs indicate that high-MUFA
diets are associated with improved glyce-
mic control and improved CVD risk or
risk factors (70,169–171). The intake of
MUFA-rich foods as a component of the
Mediterranean-style eating pattern has
been studied extensively over the last de-
cade. Six published RCTs that included
individuals with type 2 diabetes reported
improved glycemic control and/or blood
lipids when MUFA was substituted for
carbohydrate and/or saturated fats
(70,72,83,100,108,172). However, some
of the studies also included caloric restric-
tion, which may have contributed to im-
provements in glycemic control or blood
lipids (100,108).
In 2011, the Evidence Analysis Li-
brary (EAL) of the Academy of Nutrition
and Dietetics found strong evidence that
dietary MUFAs are associated with im-
provements in blood lipids based on 13
studies including participants with and
without diabetes. According to the EAL,
5% energy replacement of saturated fatty
acid (SFA) with MUFA improves insulin
responsiveness in insulin-resistant and
type 2 diabetic subjects (173).
There is limited evidence in people
with diabetes on the effects of omega-6
polyunsaturated fatty acids (PUFAs).
Controversy exists on the best ratio of
omega-6 to omega-3 fatty acids; PUFAs
and MUFAs are recommended substi-
tutes for saturated or trans fat (105,174).
Omega-3 fatty acids
c Evidence does not support recom-
mending omega-3 (EPA and DHA)
supplements for people with diabetes
for the prevention or treatment of car-
diovascular events. (A)
c As recommended for the general
public, an increase in foods containing
long-chain omega-3 fatty acids (EPA and
DHA) (from fatty fish) and omega-3
linolenic acid (ALA) is recommended
for individuals with diabetes because
of their beneficial effects on lipoproteins,
prevention of heart disease, and associ-
ations with positive health outcomes in
observational studies. (B)
c The recommendation for the general
public to eat fish (particularly fatty fish)
at least two times (two servings) per
week is also appropriate for people
with diabetes. (B)
The ADA systematic review identified
seven RCTs and one single-arm study
(2002–2010) using omega-3 fatty acid
supplements and one cohort study on
whole-food omega-3 intake. In individuals
with type 2 diabetes (88), supplementa-
tion with omega-3 fatty acids did not im-
prove glycemic control, but higher-dose
supplementation decreased triglycerides.
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Additional blood-derived markers of CVD
risk were not consistently altered in these
trials. In subjects with diabetes, six short-
duration (30 days to 12 weeks) RCTs were
published after the macronutrient review
comparing omega-3 (EPA andDHA) sup-
plements to placebo and reported mini-
mal or no beneficial effects (175,176) or
mixed/inconsistent beneficial effects
(177–180) on CVD risk factors and other
health issues (e.g., depression). Supple-
mentation with flaxseed (32 g/day) or flax-
seed oil (13 g/day) for 12 weeks did not
affect glycemic control or adipokines (181).
Three longer-duration studies (4 months
[182]; 40 months [183]; 6.2 years [184])
also reported mixed outcomes. Two stud-
ies reported no beneficial effects of supple-
mentation (183,184). In one study,
patients with type 2 diabetes were ran-
domized to atorvastatin or placebo and/
or omega-3 supplements (2 g/day) or pla-
cebo. No differences on estimated 10-year
CVD risks were observed with the addition
of omega-3 fatty acid supplements com-
pared with placebo (182). In the largest
and longest trial, in patients with type 2
diabetes, supplementation with 1 g/day
omega-3 fatty acids comparedwith placebo
did not reduce the rate of cardiovascular
events, death from any cause, or death
from arrhythmia (184). However, in one
study in postmyocardial patients with
diabetes, low-dose supplementation of
omega-3 fatty acids (400 mg/day) exerted
a protective effect on ventricular arrhythmia–
related events, and a reduction in mortality
was reported (183). Thus, RCTs do not
support recommending omega-3 supple-
ments for primary or secondary prevention
of CVD despite the strength of evidence
from observational and preclinical studies.
Studies in persons with diabetes on
the effect of foods containing marine-
derived omega-3 fatty acid or the plant-
derived omega-3 fatty acid, a-linolenic
acid, are limited. Previous studies using
supplements had shown mixed effects
on fasting blood glucose and A1C levels.
However, a study comparing diets with a
high proportion of omega-3 (fatty fish)
versus omega-6 (lean fish and fat-containing
linoleic acid) fatty acids reported both diets
had no detrimental effect on glucose mea-
sures, and both diets improved insulin sen-
sitivity and lipoprotein profiles (185).
Saturated fat, dietary cholesterol,
and trans fat
c The amount of dietary saturated fat,
cholesterol, and trans fat recommended
for people with diabetes is the same
as that recommended for the general
population. (C)
Few research studies have explored
the relationship between the amount of
SFA in the diet and glycemic control
and CVD risk in people with diabetes. A
systematic review by Wheeler et al. found
just one small 3-week study that compared a
low-SFA diet (8% of total kcal) versus a
high-SFA diet (17% of total kcal) and
found no significant difference in glyce-
mic control and most CVD risk measures
(88,186).
In addition, there is limited research
regarding optimal dietary cholesterol and
trans fat intake in people with diabetes.
One large prospective cohort study (171)
in women with type 2 diabetes found a
37% increase in CVD risk for every 200
mg cholesterol/1,000 kcal.
Due to the lack of research in this
area, people with diabetes should follow
the guidelines for the general population.
TheDietary Guidelines for Americans, 2010
(105) recommends consuming less than
10% of calories from SFAs to reduce CVD
risk. Consumers can meet this guideline
by replacing foods high in SFA (i.e., full-
fat dairy products, butter, marbled meats
and bacon, and tropical oils such as co-
conut and palm) with items that are rich
in MUFA and PUFA (i.e., vegetable and
nut oils including canola, corn, safflower,
soy, and sunflower; vegetable oil spreads;
whole nuts and nut butters, and avo-
cado). CVD is a common cause of death
among individuals with diabetes. As a re-
sult, individuals with diabetes are encour-
aged to follow nutrition recommendations
similar to the general population tomanage
CVD risk factors. These recommenda-
tions include reducing SFAs to ,10%
of calories, aiming for ,300 mg dietary
cholesterol/day, and limiting trans fat as
much as possible (105).
Plant stanols and sterols
c Individuals with diabetes and dyslipi-
demia may be able to modestly reduce
total and LDL cholesterol by consuming
1.6–3 g/day of plant stanols or sterols
typically found in enriched foods. (C)
Plant sterol and stanol esters block
the intestinal absorption of dietary and
biliary cholesterol (3). Currently, the EAL
from the Academy of Nutrition and Die-
tetics recommends individuals with dys-
lipidemia incorporate 2–3 g of plant sterol
and stanol esters per day as part of a car-
dioprotective diet through consumption of
plant sterol and stanol ester–enriched
foods (187). This recommendation,
though not specific to people with diabe-
tes, is based on a review of 20 clinical
trials (187). Furthermore, the academy
reviewed 28 studies that showed no
adverse effects with plant stanol/sterol
consumption (187).
There is a much smaller body of
evidence regarding the cardioprotective
effects of phytosterol/stanol consump-
tion specifically in people with diabetes.
Beneficial effects on total, LDL choles-
terol, and non-HDL cholesterol have
been observed in four RCTs (188–
191). These studies used doses of 1.6–
3 g of phytosterols or stanols per day,
and interventions lasted 3–12 weeks.
Two of these studies were in people
with type 1 diabetes (188,189), and
one found an added benefit to choles-
terol reduction in those who were al-
ready on statin treatment (189). In
addition, two RCTs compared the effi-
cacy of plant sterol consumption (1.8 g
daily) in subjects with type 2 diabetes
and subjects without diabetes (191,
192). Neither study found a difference
in lipid profiles between the two groups,
suggesting that efficacy of this treatment
is similar for those with and without
diabetes who are hypercholesterolemic
(191,192).
A wide range of foods and beverages
are now available that contain plant
sterols including many spreads, dairy
products, grain and bread products, and
yogurt. These products can contribute a
considerable amount of calories. If used,
patients should substitute them for
comparable foods they eat in order to




c There is no clear evidence of benefit
from vitamin or mineral supplementa-
tion in people with diabetes who do not
have underlying deficiencies. (C)
o Routine supplementation with
antioxidants, such as vitamins E
and C and carotene, is not advised
because of lack of evidence of ef-
ficacy and concern related to long-
term safety. (A)
o There is insufficient evidence to
support the routine use of micro-
nutrients such as chromium, mag-
nesium, and vitamin D to improve
glycemic control in people with
diabetes. (C)
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o There is insufficient evidence to
support the use of cinnamon or
other herbs/supplements for the
treatment of diabetes. (C)
o It is recommended that individual-
ized meal planning include opti-
mization of food choices to meet
recommended dietary allowance/
dietary reference intake for all mi-
cronutrients. (E)
There currently exists insufficient ev-
idence of benefit from vitamin or mineral
supplementation in people with or with-
out diabetes in the absence of an un-
derlying deficiency (3,193,194). Because
uncontrolled diabetes is often associated
with micronutrient deficiencies (195),
people with diabetes should be aware of
the importance of acquiring daily vitamin
and mineral requirements from natural
food sources and a balanced diet (3).
For select groups of individuals such as
the elderly, pregnant or lactating women,
vegetarians, and those on calorie-restricted
diets, a multivitamin supplement may be
necessary (196).
While there has been significant in-
terest in antioxidant supplementation as a
treatment for diabetes, current evidence
not only demonstrates a lack of benefit
with respect to glycemic control and pro-
gression of complications, but also pro-
vides evidence of potential harm of
vitamin E, carotene, and other antioxi-
dant supplements (197–203).
Findings from supplement studies
with micronutrients such as chromium,
magnesium, and vitamin D are conflicting
and confounded by differences in dosing,
micronutrient levels achieved with sup-
plementation, baseline micronutrient
status, and/or methodologies used. A sys-
tematic review on the effect of chromium
supplementation on glucose metabolism
and lipids concluded that larger effects
were more commonly observed in poor-
quality studies and that evidence is limited
by poor study quality and heterogeneity in
methodology and results (204). Evidence
from clinical studies evaluating magnesium
(205,206) andvitaminD (207–211) supple-
mentation to improve glycemic control in
people with diabetes is likewise conflicting.
A systematic review (212) evaluating
the effects of cinnamon in people with di-
abetes concluded there is currently insuf-
ficient evidence to support its use, and
there is a lack of compelling evidence for
the use of other herbal products for the
improvement of glycemic control in peo-
ple with diabetes (213). It is important to
consider that herbal products are not stan-
dardized and vary in the content of active
ingredients and may have the potential to
interact with other medications (214).
Therefore, it is important that patients/
clients with diabetes report the use of
supplements and herbal products to their
health care providers.
Alcohol
c If adults with diabetes choose to drink
alcohol, they should be advised to do
so in moderation (one drink per day or
less for adult women and two drinks per
day or less for adult men). (E)
c Alcohol consumption may place peo-
ple with diabetes at increased risk for
delayed hypoglycemia, especially if tak-
ing insulin or insulin secretagogues.
Education and awareness regarding the
recognition and management of delayed
hypoglycemia is warranted. (C)
Moderate alcohol consumption has
minimal acute and/or long-term detri-
mental effects on blood glucose in people
with diabetes (215–219), with some epi-
demiologic data showing improved glyce-
mic control with moderate intake.
Moderate alcohol intake may also convey
cardiovascular risk reduction and mortal-
ity benefits in people with diabetes (220–
223), with the type of alcohol consumed
not influencing these beneficial effects
(221,224). Accordingly, the recommen-
dations for alcohol consumption for peo-
ple with diabetes are the same as for the
general population. Adults with diabetes
choosing to consume alcohol should limit
their intake to one serving or less per day
for women and two servings or less per
day for men (105). Excessive amounts of
alcohol ($3 drinks/day) consumed on a
consistent basis may contribute to hyper-
glycemia (221). One alcohol-containing
beverage is defined as 12 oz beer, 5 oz
wine, or 1.5 oz distilled spirits, each con-
taining approximately 15 g of alcohol.
Abstention from alcohol should be ad-
vised, however, for people with a history
of alcohol abuse or dependence, women
during pregnancy, and people with med-
ical conditions such as liver disease, pan-
creatitis, advanced neuropathy, or severe
hypertriglyceridemia (3).
Despite the potential glycemic and
cardiovascular benefits of moderate alco-
hol consumption, use may place people
with diabetes at increased risk for delayed
hypoglycemia. This is particularly true in
those using insulin or insulin secretagogue
therapies. Consuming alcohol with food
can minimize the risk of nocturnal hypo-
glycemia (3,225–227). Individuals with di-
abetes should receive education regarding
the recognition and management of de-
layed hypoglycemia and the potential
need for more frequent self-monitoring of
blood glucose after consuming alcoholic
beverages.
Sodium
c The recommendation for the general
population to reduce sodium to less than
2,300 mg/day is also appropriate for
people with diabetes. (B)
c For individuals with both diabetes
and hypertension, further reduction in so-
diumintake should be individualized. (B)
Limited studies have been published
on sodium reduction in people with di-
abetes. A Cochrane review of RCTs found
that decreasing sodium intake reduces
blood pressure in those with diabetes
(228). Likewise, a small study in people
with type 2 diabetes showed that follow-
ing the DASH diet and reducing sodium in-
take to about 2,300mg led to improvements
in blood pressure and other measures on
cardiovascular risk factors (46).
Incrementally lower sodium intakes
(i.e., to 1,500 mg/day) show more bene-
ficial effects on blood pressure (104,229);
however, some studies in people with
type 1 (230) and type 2 (231) diabetes
measuring urine sodium excretion have
shown increased mortality associated
with the lowest sodium intakes, there-
fore warranting caution for universal so-
dium restriction to 1,500 mg in this
population. Additionally, an IOM report
suggests there is no evidence on health
outcomes to treat certain population
subgroupsdwhich includes individuals
with diabetesddifferently than the gen-
eral U.S. population (232).
In the absence of clear scientific evi-
dence for benefit in people with combined
diabetes and hypertension (230,231), so-
dium intake goals that are significantly
lower than 2,300 mg/day should be con-
sidered only on an individual basis. When
individualizing sodium intake recommen-
dations, consideration must also be given
to issues such as the palatability, availability,
and additional cost of specialty low sodium
products and the difficulty in achieving
both low sodium recommendations and a
nutritionally adequate diet given these
limitations (233).
While specific dietary sodium tar-
gets are highly debated by various health
groups, all agree that the current average
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Table 4dSummary of priority topics
1. Strategies for all people with diabetes:
c Portion control should be recommended for weight loss and maintenance.
c Carbohydrate-containing foods and beverages and endogenous insulin production are the greatest determinant of the postmeal blood glucose
level; therefore, it is important to know what foods contain carbohydratesdstarchy vegetables, whole grains, fruit, milk and milk products,
vegetables, and sugar.
c When choosing carbohydrate-containing foods, choose nutrient-dense, high-fiber foods whenever possible instead of processed foods with
added sodium, fat, and sugars. Nutrient-dense foods and beverages provide vitamins, minerals, and other healthful substances with relatively
few calories. Calories have not been added to them from solid fats, sugars, or refined starches.
c Avoid SSBs.
c Formost people, it is not necessary to subtract the amount of dietary fiber or sugar alcohols from total carbohydrates when carbohydrate counting.
c Substitute foods higher in unsaturated fat (liquid oils) for foods higher in trans or saturated fat.
c Select leaner protein sources and meat alternatives.
c Vitamin and mineral supplements, herbal products, or cinnamon to manage diabetes are not recommended due to lack of evidence.
c Moderate alcohol consumption (one drink/day or less for adult women and two drinks or less for adult men) has minimal acute or long-term
effects on blood glucose in people with diabetes. To reduce risk of hypoglycemia for individuals using insulin or insulin secretagogues, alcohol
should be consumed with food.
c Limit sodium intake to 2,300 mg/day.
2. Priority should be given to coordinating food with type of diabetes medicine for those individuals on medicine.
c For individuals who take insulin secretagogues:
o Moderate amounts of carbohydrate at each meal and snacks.
o To reduce risk of hypoglycemia:*
▪ Eat a source of carbohydrates at meals.
▪ Moderate amounts of carbohydrates at each meal and snacks.
▪ Do not skip meals.
▪ Physical activity may result in low blood glucose depending on when it is performed. Always carry a source of carbohydrates to reduce
risk of hypoglycemia.*
c For individuals who take biguanides (metformin):
o Gradually titrate to minimize gastrointestinal side effects when initiating use:
▪ Take medication with food or 15 min after a meal if symptoms persist.
▪ If side effects do not resolve over time (a few weeks), follow up with health care provider.
▪ If taking along with an insulin secretagogue or insulin, may experience hypoglycemia.*
c For individuals who take a-glucosidase inhibitors:
o Gradually titrate to minimize gastrointestinal side effects when initiating use.
o Take at start of meal to have maximal effect:
▪ If taking along with an insulin secretagogue or insulin, may experience hypoglycemia.
▪ If hypoglycemia occurs, eat something containingmonosaccharides such as glucose tablets as drugwill prevent the digestion of polysaccharides.
c For individuals who take incretin mimetics (GLP-1):
o Gradually titrate to minimize gastrointestinal side effects when initiating use:
▪ Injection of daily or twice-daily GLP-1s should be premeal.
▪ If side effects do not resolve over time (a few weeks), follow up with health care provider.
▪ If taking along with an insulin secretagogue or insulin, may experience hypoglycemia.*
▪ Once-weekly GLP-1s can be taken at any time during the day regardless of meal times.
c For individuals with type 1 diabetes and insulin-requiring type 2 diabetes:
o Learn how to count carbohydrates or use another meal planning approach to quantify carbohydrate intake. The objective of using such
a meal planning approach is to “match” mealtime insulin to carbohydrates consumed.
o If on a multiple-daily injection plan or on an insulin pump:
▪ Take mealtime insulin before eating.
▪ Meals can be consumed at different times.
▪ If physical activity is performedwithin 1– 2 h ofmealtime insulin injection, this dosemay need to be lowered to reduce risk of hypoglycemia.*
o If on a premixed insulin plan:
▪ Insulin doses need to be taken at consistent times every day.
▪ Meals need to be consumed at similar times every day.
▪ Do not skip meals to reduce risk of hypoglycemia.
▪ Physical activity may result in low blood glucose depending on when it is performed. Always carry a source of quick-acting
carbohydrates to reduce risk of hypoglycemia.*
o If on a fixed insulin plan:
▪ Eat similar amounts of carbohydrates each day to match the set doses of insulin.
GLP-1, glucagon-like peptide-1. *Treatment of hypoglycemia: current recommendations include the use of glucose tablets or carbohydrate-containing foods or
beverages (such as fruit juice, sports drinks, regular soda pop, or hard candy) to treat hypoglycemia. A commonly recommended dose of glucose is 15–20 g. When
blood glucose levels are;50–60 mg/dL, treatment with 15 g of glucose can be expected to raise blood glucose levels;50 mg/dL (239). If self-monitoring of blood
glucose and about 15–20 min after treatment shows continued hypoglycemia, the treatment should be repeated.
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intake of sodium of 3,400 mg/day (ex-
cluding table salt) is excessive and
should be reduced (105,234–237). The
food industry can play a major role in
lowering sodium content of foods to help
people meet sodium recommendations
(233,234).
Clinical priorities for
nutrition management for all
people with diabetesdA wide
range of diabetes meal planning ap-
proaches or eating patterns have been
shown to be clinically effective, with
many including a reduced energy intake
component. There is not one ideal per-
centage of calories from carbohydrates,
protein, or fat that is optimal for all people
with diabetes. Nutrition therapy goals
should be developed collaboratively
with the individual with diabetes and be
based on an assessment of the individual’s
current eating patterns, preferences, and
metabolic goals. Once a thorough as-
sessment is completed, the health care
professional’s role is to facilitate behav-
ior change and achievement of meta-
bolic goals while meeting the patient’s
preferences, which may include allow-
ing the patient to continue following
his/her current eating pattern. If the in-
dividual would like to try a different
eating pattern, this should also be sup-
ported by the health care team. Various
behavior change theories and strategies
can be used to tailor nutrition interven-
tions to help the client achieve specific
health and quality-of-life outcomes
(238).
Multiple meal planning approaches
and eating patterns can be effective for
achieving metabolic goals. Examples in-
clude: carbohydrate counting, healthful
food choices/simplified meal plans
(i.e., the Plate Method), individualized
meal planning methods based on per-
centages of macronutrients, exchange
list for meal planning, glycemic index,
and eating patterns including Mediter-
ranean style, DASH, vegetarian or
vegan, low carbohydrate, and low fat.
The meal planning approach or eating
pattern should be selected based on the
individual’s personal and cultural pref-
erences; literacy and numeracy; and
readiness, willingness, and ability to
change. This may need to be adjusted
over time based on changes in life cir-
cumstances, preferences, and disease
course.
A summary of key topics for nutrition
education can be found in Table 4.
Future research
directionsdThe evidence presented
in this position statement concurs with
the review previously published by
Wheeler et al. (88) that many different
approaches to nutrition therapy and eat-
ing patterns are effective for the target
outcomes of improved glycemic control
and reduced CVD risk among individu-
als with diabetes. Evaluating nutrition
evidence is complex given that multiple
dietary factors influence glycemic con-
trol and CVD risk factors, and the in-
fluence of a combination of factors can
be substantial. Based on a review of the
evidence, it is clear that gaps in the liter-
ature continue to exist and further re-
search on nutrition and eating patterns
is needed in individuals with type 1 and
type 2 diabetes.
For example, future studies should
address:
c The relationships between eating pat-
terns and disease in diverse populations.
c The basis for the beneficial effects of
the Mediterranean-style eating pattern
and approaches to translation of the
Mediterranean-style eating pattern into
diverse populations.
c The development of standardized def-
initions for high– and low–glycemic
index diets and implementation of
these definitions in long-term studies
to further evaluate their impact on
glycemic control.
c The development of standardized defi-
nitions for low- tomoderate-carbohydrate
diets and determining long-term sus-
tainability.
c Whether NNSs, when used to replace
caloric sweeteners, are useful in re-
ducing caloric and carbohydrate in-
take.
c The impact of key nutrients on car-
diovascular risk, such as saturated fat,
cholesterol, and sodium in individuals
with both type 1 and type 2 diabetes.
c Intake of SFA and its relationship to
insulin resistance.
Importantly, research needs to move
away from just evaluating the impact of
individual nutrients on glycemic control
and cardiovascular risk. More research on
eating patterns, unrestricted and restricted
energy diets, and diverse populations is
needed to evaluate their long-term health
benefits in individuals with diabetes.
Individuals eat nutrients from foods
and within the context of mixed meals,
and nutrient intakes are intercorrelated,
so overall eating patternsmust be studied
to fully understand how these eating
patterns impact glycemic control (88,
240). Eating patterns are selected by in-
dividuals based on more than the health-
fulness of food and food availability;
tradition, cultural food systems, health
beliefs, and economics are also impor-
tant (95). Studies on gene-diet interac-
tions will also be important, as well as
studies on potential epigenetic effects
that depend on nutrients to moderate
gene expression.
Given the benefits of both nutrition
therapy and MNT for individuals with
diabetes, it is also important to study
systematic processes within the context of
health care delivery that encourage more
individuals with diabetes to receive nu-
trition therapy initially, upon diagnosis,
and long term. Further research is also
needed on the best tools and strategies for
educating individuals with diabetes (e.g.,
the Plate Method) and how to improve
adherence to healthful eating patterns
among individuals with diabetes. This
research should include multiple settings
that can impact food choices for individ-
uals with diabetes, such as where they
live, work, learn, and play. Individuals
with diabetes spend the majority of their
time outside health care settings so more
research on how public health, the health
care system, and the community can
support individuals with diabetes in their
efforts to achieve healthful eating is
needed.
In summarydThere is no standard
meal plan or eating pattern that works
universally for all people with diabetes
(1). In order to be effective, nutrition ther-
apy should be individualized for each
patient/client based on his or her individ-
ual health goals; personal and cultural
preferences (241,242); health literacy
and numeracy (243,244); access to
healthful choices (245,246); and readi-
ness, willingness, and ability to change.
Nutrition interventions should emphasize
a variety of minimally processed nutrient-
dense foods in appropriate portion sizes
as part of a healthful eating pattern and
provide the individual with diabetes with
practical tools for day-to-day food plan
and behavior change that can be main-
tained over the long term.
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